We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
aTyr Pharma Inc | NASDAQ:LIFE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.04 | 2.41% | 1.70 | 1.67 | 1.72 | 1.7099 | 1.64 | 1.69 | 256,475 | 00:32:34 |
SAN DIEGO, Nov. 10, 2015 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced operating results for the third quarter and nine months ended September 30, 2015.
Clinical Highlights and Upcoming Milestones:
Additional Operational Highlights:
Third Quarter Results
Research and development expenses were $7.7 million for the quarter ended September 30, 2015, as compared to $4.4 million for the same period in 2014. The increase was primarily due to an additional $2.3 million related to manufacturing costs and clinical development incurred in support of various activities for Resolaris and an $0.8 million increase related to compensation expenses resulting from increased headcount in research and development functions, including $0.3 million in non-cash stock-based compensation.
The Company expects its research and development expense to continue to increase with its Resolaris franchise expansion activities, including the expanding clinical development of Resolaris, the first protein therapeutic from the Resokine Pathway; advancements in the development of a second program leveraging the Resokine pathway using an iMod.Fc protein therapeutic, as well as other therapeutic modalities to harness the power of the pathway in muscle or lung disease; and continued engagement in additional research and development activities relating to the therapeutic applications of Physiocrines beyond the Resokine pathway.
General and administrative expenses were $3.6 million and $1.8 million for the quarters ended September 30, 2015 and 2014, respectively. The change of $1.8 million was due primarily to a $0.7 million increase in personnel costs resulting from increased headcount, including $0.3 million in non-cash stock-based compensation. Another $0.4 million was associated with increased public company costs and intellectual property-related projects.
The Company expects general and administrative expenses to increase substantially to support the continued development of its product candidates and the costs associated with operating as a public company, which include supporting regulatory and listing requirements, insurance and investor relations. These increases will also include the cost of additional personnel and fees to outside consultants, among other expenses.
Year-To-Date Results
Research and development expenses for the nine months ended September 30, 2015 and 2014 were $21.8 million and $12.4 million, respectively. The increase of $9.4 million was due primarily to a $5.2 million increase related to manufacturing costs and clinical development incurred in support of various activities for Resolaris; a $2.5 million increase related to compensation expenses, including $1.0 million of non-cash stock-based compensation expense; and a one-time $1.4 million non-cash expense for the assignment of certain intellectual property rights.
General and administrative expenses were $9.3 million and $5.1 million for the nine months ended September 30, 2015 and 2014, respectively. The change of $4.2 million was due primarily to a $1.8 million increase in personnel costs resulting from increased headcount, including $0.7 million in stock-based compensation; a $1.4 million increase in public company costs and a $0.4 million increase in intellectual property-related projects.
Net losses for the first nine months of 2015 were $31.5 million, as compared to $18.3 million for the same period in 2014.
As of September 30, 2015, the number of shares outstanding was 23.6 million and the Company had cash, cash equivalents and investments totaling $136.8 million.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris, is a first-in-class intravenous protein therapeutic for the treatment of RMICs. Resolaris is currently in a Phase 1b/2 clinical trial in adult patients with FSHD; a Phase 1b/2 trial in adult patients with LGMD2B or FSHD; and a Phase 1b/2 trial in patients with an early onset form of FSHD. An initial trial is planned in rare pulmonary diseases with an immune component (RPIC) in patients with interstitial lung disease (ILD). To protect this pipeline, aTyr built an intellectual property estate comprising 45 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the potential of Resolaris, the ability of the Company to undertake certain development activities (such as clinical trial enrollment and the conduct of clinical trials) and accomplish certain development goals, and the timing of initiation of additional clinical trials and of reporting results from our clinical trials reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our Physiocrine-based product candidates, as well as those set forth in the prospectus for our recent offering of common stock and our most recent Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
ATYR PHARMA INC. | ||||||||
Condensed Consolidated Statements of Operations | ||||||||
(unaudited, in thousands, except share and per share data) | ||||||||
Three Months Ended |
Nine Months Ended | |||||||
September 30, |
September 30, | |||||||
2015 |
2014 |
2015 |
2014 | |||||
Operating expenses: |
||||||||
Research and development |
$ 7,739 |
$ 4,410 |
$ 21,834 |
$ 12,436 | ||||
General and administrative |
3,574 |
1,821 |
9,299 |
5,088 | ||||
Total operating expenses |
11,313 |
6,231 |
31,133 |
17,524 | ||||
Loss from operations |
(11,313) |
(6,231) |
(31,133) |
(17,524) | ||||
Other income (expenses), net |
(16) |
(400) |
(347) |
(788) | ||||
Net loss |
(11,329) |
(6,631) |
(31,480) |
(18,312) | ||||
Accretion to redemption value of redeemable convertible |
- |
(139) |
(15) |
(416) | ||||
Net loss attributable to common stockholders |
$ (11,329) |
$ (6,770) |
$ (31,495) |
$ (18,728) | ||||
Net loss per share attributable to common stockholders, |
$ (0.48) |
$ (8.02) |
$ (2.38) |
$ (22.73) | ||||
Weighted average shares outstanding, basic and diluted |
23,581,001 |
843,817 |
13,221,551 |
824,062 | ||||
ATYR PHARMA INC. |
||||||||
Condensed Consolidated Balance Sheets |
||||||||
(in thousands) |
||||||||
September 30, |
December 31, |
|||||||
2015 |
2014 |
|||||||
(unaudited) |
||||||||
Cash, cash equivalents and investments |
$ 136,813 |
$ 15,853 |
||||||
Other assets |
2,715 |
2,866 |
||||||
Property and equipment, net |
1,841 |
1,925 |
||||||
Total assets |
$ 141,369 |
$ 20,644 |
||||||
Accounts payable, accrued expenses and other liabilities |
$ 6,265 |
$ 5,759 |
||||||
Current portion of commercial bank debt |
3,307 |
3,134 |
||||||
Convertible promissory note |
— |
2,000 |
||||||
Commercial bank debt, net of current portion |
2,640 |
5,142 |
||||||
Redeemable convertible preferred stock |
— |
95,619 |
||||||
Stockholders'equity (deficit) |
129,157 |
(91,010) |
||||||
Total liabilities and stockholders'equity (deficit) |
$ 141,369 |
$ 20,644 |
||||||
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atyr-pharma-announces-third-quarter-2015-operating-results-300176096.html
SOURCE aTyr Pharma, Inc.
Copyright 2015 PR Newswire
1 Year aTyr Pharma Chart |
1 Month aTyr Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions